Laquinimod Disappoints Again, This Time In Huntington's Disease
Executive Summary
Laquinimod fails to impress in a Phase II study in Huntington's disease, adding to a series of clinical trial setbacks over past years for the potential oral immunomodulator.
You may also be interested in...
Vaccinex Sees Mixed Signals In Huntington’s Study
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
Finance Watch: Vaccinex, Aridis Launch August's First US IPOs As The Summer Simmer Slows
The summer slowdown finally seems to have hit the US biopharma IPO market; after a hot July with nine offerings, there were just two during the first half of August. Also, Zogenix leads recent follow-ons with a $312m offering; venture capital planted in UK biotechs – Orchard and Blueberry.
Ionis/Roche's Huntington's Drug 'Next Spinraza'?
Further details of a Phase I/II study results are raising hopes that it could be the first disease-modifying treatment for the disease, but it is not yet known whether the reduction in Huntintin seen will translate into a clinical benefit.